184 related articles for article (PubMed ID: 30863015)
21. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological inhibition of 17β-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model.
Xanthoulea S; Konings GFJ; Saarinen N; Delvoux B; Kooreman LFS; Koskimies P; Häkkinen MR; Auriola S; D'Avanzo E; Walid Y; Verhaegen F; Lieuwes NG; Caiment F; Kruitwagen R; ; Romano A
Cancer Lett; 2021 Jun; 508():18-29. PubMed ID: 33762202
[TBL] [Abstract][Full Text] [Related]
23. Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown.
Han H; Thériault JF; Chen G; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():36-45. PubMed ID: 28554725
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Husen B; Huhtinen K; Poutanen M; Kangas L; Messinger J; Thole H
Mol Cell Endocrinol; 2006 Mar; 248(1-2):109-13. PubMed ID: 16406284
[TBL] [Abstract][Full Text] [Related]
25. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
26. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
Konings GF; Cornel KM; Xanthoulea S; Delvoux B; Skowron MA; Kooreman L; Koskimies P; Krakstad C; Salvesen HB; van Kuijk K; Schrooders YJ; Vooijs M; Groot AJ; Bongers MY; Kruitwagen RF; ; Romano A
J Pathol; 2018 Feb; 244(2):203-214. PubMed ID: 29144553
[TBL] [Abstract][Full Text] [Related]
27. Chemical synthesis, characterisation and biological evaluation of furanic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Farhane S; Laplante Y; Poirier D
Med Chem; 2011 Mar; 7(2):80-91. PubMed ID: 21222612
[TBL] [Abstract][Full Text] [Related]
28. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
29. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
[TBL] [Abstract][Full Text] [Related]
30. An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis.
Poirier D; Nyachieo A; Romano A; Roy J; Maltais R; Chai D; Delvoux B; Tomassetti C; Vanhie A
J Steroid Biochem Mol Biol; 2022 Sep; 222():106136. PubMed ID: 35691460
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
[TBL] [Abstract][Full Text] [Related]
32. Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17β-hydroxysteroid dehydrogenase type 1.
Herman BE; Szabó J; Bacsa I; Wölfling J; Schneider G; Bálint M; Hetényi C; Mernyák E; Szécsi M
J Enzyme Inhib Med Chem; 2016; 31(sup3):61-69. PubMed ID: 27424610
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
34. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
[TBL] [Abstract][Full Text] [Related]
35. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
36. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Reed MJ; Potter BV
Mol Cell Endocrinol; 2006 Mar; 248(1-2):204-7. PubMed ID: 16337736
[TBL] [Abstract][Full Text] [Related]
37. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
[TBL] [Abstract][Full Text] [Related]
38. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
39. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
40. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.
Breton R; Housset D; Mazza C; Fontecilla-Camps JC
Structure; 1996 Aug; 4(8):905-15. PubMed ID: 8805577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]